Metastatic Prostate Cancer

Enzalutamide conferred small but statistically significant improvements in outcomes vs. abiraterone acetate for men with metastatic castration-resistant prostate cancer, according to retrospective study results.

The addition of talazoparib to enzalutamide extended OS among men with metastatic castration-resistant prostate cancer, according to the agent’s manufacturer.

A blood test for men at the time of a metastatic prostate cancer diagnosis may predict treatment response and survival, according to study results.

The addition of six cycles of radium-223 to first-line enzalutamide extended radiographic PFS for men with metastatic castration-resistant prostate cancer, according to results of a randomized phase 3 trial.

Olaparib monotherapy may be an effective treatment option for certain men with biochemically recurrent prostate cancer, according to results of a nonrandomized phase 2 trial.

Men with bone pain at diagnosis of metastatic, hormone-resistant prostate cancer had shorter survival than men without bone pain, according to study results.

Rates of next-generation sequencing have increased for individuals with metastatic prostate cancer or advanced urothelial carcinoma over the past several years, but more than half of these individuals still do not undergo testing.

CHICAGO — In this Healio video exclusive, Silke Gillessen, MD, discusses how identification of early surrogate measures for long-term outcomes in prostate cancer could identify patients who require therapy escalation or can be de-escalated.

In this edition, precision navigators reduce racial disparities in genomic testing; cancer diagnoses fell sharply during early days of pandemic; Prostate Cancer Awareness Month updates, and more.

Black men with metastatic castration-resistant prostate cancer appear less likely to receive targeted therapies than white men, according to data published in JAMA Network Open.